A new research perspective was published in Oncotarget’s Volume 14 on August 7, 2023, entitled, “CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies.”
Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis – Pharmaceutical Technology
Dr. Jawad Haider Butt shared data demonstrating that a patient’s duration of living with type 2 diabetes does not impact treatment response to Forxiga. Credit:
August 31, 2024